Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 13 Apr 2015

Humabs and MedImmune partnership to develop an Influenza A treatment

Medimmune starts phase I clinical trial to investigate an antibody developed under a collaboration with Humabs BioMed for the treatment of influenza A. The novel antibody developed through Humabs’ Cellclone technology will be investigated a trial being conducted by MedImmune, the global biologics research and development arm of AstraZeneca. The investigational antibody, which has broad influenza-neutralizing […]

April 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Apr 2015

FuturaGene’s Genetically Modified Eucalyptus approved in Brazil

The Brazilian National Technical Commission on Biosafety (CTNBio) approved the commercial use of the yield enhanced eucalyptus developed by FuturaGene, the leading Israeli agricultural biotech. Field experiments conducted since 2006 at various locations in Brazil have demonstrated an approximate 20% increase in yield compared to its equivalent conventional variety. This is the first genetically modified […]

April 10, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 9 Apr 2015

Ipsen and Hannover Medical School start joint research in Recombinant Botulinum Neurotoxins

Ipsen and Hannover Medical School, one of the world’s leading university medical centres, have entered into a joint research collaboration agreement, signed in last September. Their objective is to develop new therapeutics for patients with serious neurological, endocrinological or oncological disease. The research program aims at testing recombinant botulinum neurotoxin proteins to affect intracellular molecular […]

April 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Apr 2015

CRISPR Therapeutics opens Boston R&D Office to Win the CRISPR War

CRISPR Therapeutics appointed Bill Lundberg to Chief Scientific Officer to lead the company’s development programs and to spearhead the creation of its R&D operations in Cambridge, Massachusetts. The biopharmaceutical company was founded in Basel, Switzerland, by Emanuelle Charpentier, one of the pioneer scientists in the CRISPR field. The company is focused on translating CRISPR-Cas9 gene-editing […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Apr 2015

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Apr 2015

Open Bionics, lending a 3D-Printed helping hand

Little could the young Joel Gibbard have ever imagined that those Meccano games he once used to play with as a child, would one day lead him to become Britain’s Design Engineer of the Year amongst other prestigious awards. Open Bionics, the Bristol-based company he founded, aims at providing low-cost robotic hands. I got to […]

April 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 2 Apr 2015

Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

Anergis announced treatment completion of its Phase II clinical trial of AllerT, a novel long-peptide immunotherapeutic to treat birch pollen allergies. Anergis’ approach uses synthetic, pharmaceutical-grade Contiguous Overlapping Peptide (“COP”), peptides of 40-80 amino-acids which are safer (no risk of immediate allergic reaction) and can elicit a faster immune response than the allergenic proteins they […]

April 2, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 1 Apr 2015

Cardio3 will launch an IPO in the United States

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined. A draft registration statement relating to […]

April 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 27 Mar 2015

OSE Pharma raised €21.1 Million

OSE Pharma’s Initial Public Offering couldn’t have been more successful as it just raised €21.1M. Noticing the strong demand for shares, the board of OSE Pharma has increased the price of the capital to €10.80 per share, corresponding to the top of the indicative price range of the offer. On this basis, the market capitalization […]

March 27, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 26 Mar 2015

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

After successfully complete phase I clinical study, apceth initiates the Phase II of world’s first genetically-engineered cell therapy. The ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, will take place at the Klinikum Grosshadern in Munich. This is the first time that a genetically engineered Mesenchymal Stem Cell […]

March 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Mar 2015

The Genomic Portrait of Iceland

A package of four landmark papers were published yesterday in the online edition of Nature Genetics. The research, written by a team of deCODE scientists, was built on whole-genome sequence data from more than 100,000 people from across Iceland. The four milestone studies together present the most detailed portrait of a population yet assembled using the latest technology […]

March 26, 2015 - 4 minutesmins - By Lourdes Riquelme

News and Trends 25 Mar 2015

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Epigenomics, the German-American cancer molecular diagnostics company, completed the enrollment for its ADMIT trial (AD herence to Minimally Invasive Testing) for Epi proColon, its non-invasive blood-based test for colorectal cancer (CRC) screening. Epigenomics has successfully completed enrollment in the ADMIT clinical trial this week. Study subjects were identified as historically non-compliant to CRC screening according to […]

March 25, 2015 - 3 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

Humabs and MedImmune partnership to develop an Influenza A treatment

FuturaGene’s Genetically Modified Eucalyptus approved in Brazil

Ipsen and Hannover Medical School start joint research in Recombinant Botulinum Neurotoxins

CRISPR Therapeutics opens Boston R&D Office to Win the CRISPR War

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Open Bionics, lending a 3D-Printed helping hand

Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

Cardio3 will launch an IPO in the United States

OSE Pharma raised €21.1 Million

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

The Genomic Portrait of Iceland

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Lourdes Riquelme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!